QIAGEN N.V. (QGEN)
QIAGEN N.V. (QGEN) from its SEC filings: 2025 revenue $2.1 billion (+6% vs the year before), net margin 20%, free cash flow $453.3 million. Insider trades, recent filings and a price chart. Free.
| Exchange | NYSE |
| Industry | Biological Products, (No Diagnostic Substances) |
| Revenue (2025) | $2.1 billion |
| Revenue growth | +6% |
| Net income | $424.9 million |
| Net margin | 20.3% |
| Free cash flow | $453.3 million |
| Diluted EPS | $1.94 |
| Cash | $839.0 million |
| Long-term debt | $1.7 billion |
| Share count, 1 year | -2% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.